title: Clinical approach to renal study incidental to 99mTc-MDP bone scintigraphy.
abstract: In order to investigate the feasibility of the assessment of renal function with 99mTc-MDP, we compared renographical images, renogram patterns and the glomerular filtration rate (GFR) obtained by means of a modified Gates' method and 200 MBq of 99mTc-MDP with those obtained by means of 99mTc-DTPA. Because 19 of 20 patients had malignant tumors in the genitourinary tract, there was no difference between the two tracers in identifying a parenchymal defect corresponding to renal cancer. Of eight patients with hydronephrosis, four had a defect or decreased uptake with a dilated pelvis, whereas the other four had marked radioisotope retention in the renal pelvis or the whole kidney on serial images. There was also no difference between the two tracers in identifying hydronephrosis. Of 38 paired renograms 35 showed the same renogram patterns with both tracers. Of three patients with different renogram patterns, two had hydronephrosis. In 20 patients including three patients with bone metastasis, total GFR and split GFR obtained with both tracers correlated with a correlation coefficient of r = 0.920 (p < 0.001) and r = 0.944 (p < 0.001), respectively. Excluding bone metastasis from the analysis, a linear-regression analysis showed excellent agreement between the two measurements with a correlation coefficient of r = 0.960 (p < 0.001) and r = 0.963 (p < 0.001), respectively. The linear regression equations were Y = 1.009X - 0.111 and Y = 1.034X - 0.714, respectively. In conclusion, 99mTc-MDP can be used as a supplement to evaluate renal function incidental to the survey of bone metastases in patients with malignant tumor.
authors.affiliation: Department of Clinical Radiological Technology, School of Health Sciences, Kanazawa University, Japan. teruhiko@kenroku.kanazawa-u.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Takayama
authors.forename: S
authors.initials: S
authors.lastname: Kinuya
authors.forename: K
authors.initials: K
authors.lastname: Kobashi
authors.forename: M
authors.initials: M
authors.lastname: Onoguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Mizukami
authors.forename: K
authors.initials: K
authors.lastname: Koshida
authors.forename: S
authors.initials: S
authors.lastname: Tsuji
authors.forename: N
authors.initials: N
authors.lastname: Tonami
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001806:Blood Urea Nitrogen; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary*; D001842:Bone and Bones / Q000000981:diagnostic imaging*; D003404:Creatinine / Q000097:blood; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D006869:Hydronephrosis / Q000000981:diagnostic imaging; D007668:Kidney / Q000000981:diagnostic imaging*; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging; D011866:Radioisotope Renography; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D013669:Technetium Tc 99m Medronate / Q000493:pharmacokinetics; D014018:Tissue Distribution; D001749:Urinary Bladder Neoplasms / Q000000981:diagnostic imaging; D014565:Urogenital Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology
chemical_list: D019275:Radiopharmaceuticals; D003404:Creatinine; D013669:Technetium Tc 99m Medronate